Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 19/20 | 1.00 |
| ▸ | OGFRL1 | Q5TC84 | 14/20 | 1.00 |
| ▸ | OPRL1 | P41146 | 8/20 | 0.73 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.73 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lexanopadol SCHEMBL566686 | 1.00 | OPRM1 (1.00) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| Lexanopadol SCHEMBL381022 | 1.00 | OPRM1 (1.00) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| Lexanopadol SCHEMBL29930643 | 1.00 | OPRM1 (1.00) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| SCHEMBL2829900 | 0.89 | OPRM1 (0.80) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| SCHEMBL380515 | 0.87 | OPRM1 (1.00) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| SCHEMBL681581 | 0.86 | OPRM1 (0.75) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| Cebranopadol SCHEMBL566256 | 0.84 | OPRM1 (1.00) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| SCHEMBL16153874 | 0.84 | OPRM1 (0.75) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| Cebranopadol SCHEMBL154336 | 0.84 | OPRM1 (1.00) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| Cebranopadol SCHEMBL29353179 | 0.84 | OPRM1 (1.00) | OPRM1OGFRL1OPRL1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3459533-A1 | PHARMACEUTICAL DOSAGE FORM COMPRISING 6'-FLUORO-(N-METHYL- OR N,N-DIMETHYL-)-4-PHENYL-4',9'-DIHYDRO-3'H-SPIRO[CYCLOHEXANE-1,1'-PYRANO[3,4,B]INDOL]-4-AMINE FOR THE TREATMENT OF NOCICEPTIVE PAIN | Grünenthal GmbH (DE) | 2019-03-27 | — | — | EP | claimed |
| EP-2600850-B1 | PHARMACEUTICAL DOSAGE FORM COMPRISING 6'-FLUORO-(N-METHYL- OR N,N-DIMETHYL-)-4-PHENYL-4',9'-DIHYDRO-3'H-SPIRO[CYCLOHEXANE-1,1'-PYRANO[3,4,B]INDOL]-4-AMINE FOR THE TREATMENT OF NOCICEPTIVE PAIN | GRUENENTHAL GMBH (DE) | 2018-10-17 | — | — | EP | claimed |
| EP-2600851-B1 | PHARMACEUTICAL DOSAGE FORM COMPRISING 6'-FLUORO-(N-METHYL- OR N,N-DIMETHYL-)-4-PHENYL-4',9'-DIHYDRO-3'H-SPIRO[CYCLOHEXANE-1,1'-PYRANO[3,4,B]INDOL]-4-AMINE FOR THE TREATMENT OF NEUROPATHIC PAIN | GRUENENTHAL GMBH (DE) | 2018-05-02 | — | — | EP | claimed |
| EP-2600839-B1 | PHARMACEUTICAL DOSAGE FORM COMPRISING 6'-FLUORO-(N-METHYL- OR N,N-DIMETHYL-)-4-PHENYL-4',9'-DIHYDRO-3'H-SPIRO[CYLOHEXANE-1,1'-PYRANO[3,4,B]INDOL]-4-AMINE | GRUENENTHAL GMBH (DE) | 2018-01-10 | — | — | EP | claimed |
| US-9289416-B2 | Pharmaceutical dosage forms comprising 6′-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine | GRUENENTHAL GMBH (DE) | 2016-03-22 | — | — | US | claimed |
| EP-2600846-B1 | PHARMACEUTICAL DOSAGE FORM COMPRISING 6'-FLUORO-(N-METHYL- OR N,N-DIMETHYL-)-4-PHENYL-4',9'-DIHYDRO-3'H-SPIRO[CYLOHEXANE-1,1'-PYRANO[3,4,B]INDOL]-4-AMINE | GRUENENTHAL GMBH (DE) | 2015-11-25 | — | — | EP | claimed |
| EP-2600838-B1 | PHARMACEUTICAL DOSAGE FORM COMPRISING 6'-FLUORO-(N-METHYL- OR N,N-DIMETHYL-)-4-PHENYL-4',9'-DIHYDRO-3'H-SPIRO[CYCLOHEXANE-1,1'-PYRANO[3,4,B]INDOL]-4-AMINE | GRUENENTHAL GMBH (DE) | 2015-09-16 | — | — | EP | claimed |
| US-20150111939-A1 | Pharmaceutical Dosage Forms Comprising 6'-Fluoro-(N-Methyl- or N,N-Dimethyl-)-4-Phenyl-4',9'-Dihydro-3'H-Spiro[Cyclohexane-1,1'-Pyrano[3,4,b]Indol]-4-Amine | ADNEURIS THERAPEUTICS, INC. | 2015-04-23 | — | — | US | claimed |
| EP-2600851-A2 | PHARMACEUTICAL DOSAGE FORM COMPRISING 6'-FLUORO-(N-METHYL- OR N,N-DIMETHYL-)-4-PHENYL-4',9'-DIHYDRO-3'H-SPIRO[CYCLOHEXANE-1,1'-PYRANO[3,4,B]INDOL]-4-AMINE FOR THE TREATMENT OF NEUROPATHIC PAIN | Grünenthal GmbH (DE) | 2013-06-12 | — | — | EP | claimed |
| EP-2600850-A2 | PHARMACEUTICAL DOSAGE FORM COMPRISING 6'-FLUORO-(N-METHYL- OR N,N-DIMETHYL-)-4-PHENYL-4',9'-DIHYDRO-3'H-SPIRO[CYCLOHEXANE-1,1'-PYRANO[3,4,B]INDOL]-4-AMINE FOR THE TREATMENT OF NOCICEPTIVE PAIN | Grünenthal GmbH (DE) | 2013-06-12 | — | — | EP | claimed |
| EP-2600839-A2 | PHARMACEUTICAL DOSAGE FORM COMPRISING 6'-FLUORO-(N-METHYL- OR N,N-DIMETHYL-)-4-PHENYL-4,9'-DIHYDRO-3'H-SPIRO[CYLOHEXANE-1,1'-PYRANO[3,4,B]INDOL]-4-AMINE | Grünenthal GmbH (DE) | 2013-06-12 | — | — | EP | claimed |
| US-20120034297-A1 | Pharmaceutical dosage forms comprising 6'-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine | GRUENENTHAL GMBH (DE) | 2012-02-09 | — | — | US | claimed |
| WO-2012016698-A2 | PHARMACEUTICAL DOSAGE FORM COMPRISING 6'-FLUORO-(N-METHYL- OR N,N-DIMETHYL-)-4-PHENYL-4',9'-DIHYDRO-3'H-SPIRO[CYCLOHEXANE-1,1'-PYRANO[3,4,B]INDOL]-4-AMINE FOR THE TREATMENT OF NEUROPATHIC PAIN | Grünenthal GmbH (DE) | 2012-02-09 | — | — | WO | claimed |
| WO-2012016697-A2 | PHARMACEUTICAL DOSAGE FORM COMPRISING 6'-FLUORO-(N-METHYL- OR N,N-DIMETHYL-)-4-PHENYL-4',9'-DIHYDRO-3'H-SPIRO[CYCLOHEXANE-1,1'-PYRANO[3,4,B]INDOL]-4-AMINE FOR THE TREATMENT OF NOCICEPTIVE PAIN | Grünenthal GmbH (DE) | 2012-02-09 | — | — | WO | claimed |
| WO-2012016699-A2 | PHARMACEUTICAL DOSAGE FORM COMPRISING 6'-FLUORO-(N-METHYL- OR N,N-DIMETHYL-)-4-PHENYL-4,9'-DIHYDRO-3'H-SPIRO[CYLOHEXANE-1,1'-PYRANO[3,4,B]INDOL]-4-AMINE | Grünenthal GmbH (DE) | 2012-02-09 | — | — | WO | claimed |
| US-10912763-B2 | Pharmaceutical dosage forms comprising 6′-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine | Grünenthal GmbH (DE) | 2021-02-09 | — | — | US | disclosed |
| EP-3459533-A1 | PHARMACEUTICAL DOSAGE FORM COMPRISING 6'-FLUORO-(N-METHYL- OR N,N-DIMETHYL-)-4-PHENYL-4',9'-DIHYDRO-3'H-SPIRO[CYCLOHEXANE-1,1'-PYRANO[3,4,B]INDOL]-4-AMINE FOR THE TREATMENT OF NOCICEPTIVE PAIN | Grünenthal GmbH (DE) | 2019-03-27 | — | — | EP | disclosed |
| EP-2600846-A2 | PHARMACEUTICAL DOSAGE FORM COMPRISING 6'-FLUORO-(N-METHYL- OR N,N-DIMETHYL-)-4-PHENYL-4',9'-DIHYDRO-3'H-SPIRO[CYLOHEXANE-1,1'-PYRANO[3,4,B]INDOL]-4-AMINE | Grünenthal GmbH (DE) | 2013-06-12 | — | — | EP | disclosed |
| US-20120034297-A1 | Pharmaceutical dosage forms comprising 6'-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine | GRUENENTHAL GMBH (DE) | 2012-02-09 | — | — | US | disclosed |
| WO-2012016695-A2 | PHARMACEUTICAL DOSAGE FORM COMPRISING 6'-FLUORO-(N-METHYL- OR N,N-DIMETHYL-)-4-PHENYL-4',9'-DIHYDRO-3'H-SPIRO[CYLOHEXANE-1,1'-PYRANO[3,4,B]INDOL]-4-AMINE | Grünenthal GmbH (DE) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10912763-B2 | Pharmaceutical dosage forms comprising 6′-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine | HTR1B, SLC5A11, HTR6 | OPRM1 139/4885OGFRL1 2967/4885OPRL1 602/4885 |
| US-20150111939-A1 | Pharmaceutical Dosage Forms Comprising 6'-Fluoro-(N-Methyl- or N,N-Dimethyl-)-4-Phenyl-4',9'-Dihydro-3'H-Spiro[Cyclohexane-1,1'-Pyrano[3,4,b]Indol]-4-Amine | HTR1B, SLC5A11, HTR6 | OPRM1 148/4885OGFRL1 2807/4885OPRL1 621/4885 |
| US-20120034297-A1 | Pharmaceutical dosage forms comprising 6'-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine | HTR1B, SLC5A11, HTR6 | OPRM1 148/4885OGFRL1 2807/4885OPRL1 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.